Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CCR8 | P51685 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523736 | 1.00 | L3MBTL1 (0.59) | L3MBTL1PKMNPSR1TAS2R14LMNA | |
| SCHEMBL664380 | 0.87 | MEN1 (0.53) | L3MBTL1PKMNPSR1LMNAMEN1 | |
| SCHEMBL3541508 | 0.86 | L3MBTL1 (0.53) | L3MBTL1PKMNPSR1MEN1KMT2A | |
| SCHEMBL7804819 | 0.85 | MEN1 (0.55) | PKMNPSR1TAS2R14LMNAMEN1 | |
| SCHEMBL13929453 | 0.84 | ALDH1A1 (0.55) | L3MBTL1NPSR1LMNAMEN1KMT2A | |
| SCHEMBL12404098 | 0.84 | ALDH1A1 (0.55) | L3MBTL1NPSR1LMNAMEN1KMT2A | |
| SCHEMBL5522771 | 0.84 | MEN1 (0.53) | MEN1KMT2AALDH1A1POLBKDM4E | |
| SCHEMBL4653452 | 0.84 | L3MBTL1 (0.49) | L3MBTL1PKMNPSR1LMNAMEN1 | |
| SCHEMBL5532680 | 0.84 | MEN1 (0.53) | MEN1KMT2AALDH1A1POLBKDM4E | |
| SCHEMBL2374934 | 0.83 | PKM (0.52) | PKMNPSR1TAS2R14LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167452-A1 | Therapeutic amide derivatives | PFIZER, INC. | 2007-07-19 | — | — | US | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167452-A1 | Therapeutic amide derivatives | GRIN1, GRIN2B, GRIN3A | L3MBTL1 4822/4885PKM 2674/4885NPSR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.